In early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances ...

In early 2025, around 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...

In matched cohorts of more than 41,000 patients each, use of tirzepatide was linked to a significantly reduced risk of primary open-angle glaucoma compared with selective GLP-1 receptor agonists (risk ...

GLP-1 medicines have been utilised for the treatment of diabetes; however, they are now emerging as important topics for the treatment of obesity ...

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the ...

PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) ...